Literature DB >> 18155568

Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience.

Hideaki Shimada1, Tooru Shiratori, Shinichi Okazumi, Hisahiro Matsubara, Yoshihiro Nabeya, Kiyohiko Shuto, Yasunori Akutsu, Hideki Hayashi, Kaichi Isono, Takenori Ochiai.   

Abstract

BACKGROUND: Because invasion to an adjacent organ (T4) indicates highly advanced disease, and most surgeons avoid esophagectomy, the prognostic impact of clinicopathologic factors for survival of these patients after esophagectomy has rarely been analyzed. STUDY
DESIGN: From 1960 to 2005, a total of 268 patients with esophageal squamous cell carcinoma underwent esophagectomy for pathologic T4 disease (pT4). The impact of clinicopathologic factors on survival was evaluated by univariate and multivariate analysis. Changes in surgical outcomes and longterm survival between the earlier period (1960 to 1989) and the later period (1990 to 2005) were analyzed.
RESULTS: Overall survival rates of all patients were 25% at 1 year, 10% at 3 years, and 5% at 5 years. The survival curve of the later group was significantly better than that of the earlier group (p < 0.01). Multivariate analysis indicated that venous invasion (hazards ratio, 1.76; 95% CI, 1.33 to 2.33, p < 0.01) and presence of a postoperative complication (hazards ratio, 2.62; 95% CI, 1.96 to 3.51, p < 0.01) were independent risk factors for poor overall survival. Presence of residual cancer was also an independent risk factor for poor cause-specific survival (hazards ratio, 2.40; 95% CI, 1.23 to 4.69, p=0.01). Venous invasion and intramural metastasis were risk factors for residual cancer. A total of 38 (14%) patients, 15 in the early period and 23 in the later period, underwent complete resection (R0). Although overall survival after R0 resection in the later period improved slightly, cancer-related survival rates were similar in both periods.
CONCLUSIONS: Although overall survival of patients with pT4 improved after 1990, this improvement might be mainly dependent on curability of the resection.

Entities:  

Mesh:

Year:  2007        PMID: 18155568     DOI: 10.1016/j.jamcollsurg.2007.06.013

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  8 in total

1.  Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor?

Authors:  Yasunori Akutsu; Tsuguaki Kono; Masaya Uesato; Isamu Hoshino; Kentaro Murakami; Tomoyoshi Aoyagi; Takumi Ota; Takeshi Toyozumi; Hiroshi Suito; Hiroki Kobayashi; Rintaro Harada; Takashi Uno; Hisahiro Matsubara
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

2.  Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study: Reply.

Authors:  Tatsuo Matsuda; Hiroya Takeuchi
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

3.  Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.

Authors:  Takashi Suzuki; Satoshi Yajima; Nobuki Ishioka; Tatsuki Nanami; Yoko Oshima; Naohiro Washizawa; Kimihiko Funahashi; Seiko Otsuka; Tetsuo Nemoto; Hideaki Shimada
Journal:  Esophagus       Date:  2018-06-29       Impact factor: 4.230

Review 4.  Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Surg Today       Date:  2015-01-13       Impact factor: 2.549

5.  Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta.

Authors:  Hiroya Taniguchi; Kentaro Yamazaki; Narikazu Boku; Taro Funakoshi; Satoshi Hamauchi; Takahiro Tsushima; Akiko Todaka; Takeshi Sakamoto; Hideharu Tomita; Nozomu Machida; Keisei Taku; Akira Fukutomi; Yusuke Onozawa; Yasuhiro Tsubosa; Hiroshi Sato; Tetsuo Nishimura; Hirofumi Yasui
Journal:  Int J Clin Oncol       Date:  2011-02-24       Impact factor: 3.402

6.  Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Norma E Farrow; Chi-Fu J Yang; Thomas A D'Amico; David H Harpole
Journal:  Ann Thorac Surg       Date:  2019-07-26       Impact factor: 4.330

7.  Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients.

Authors:  Yasunori Akutsu; Hisahiro Matsubara; Kiyohiko Shuto; Masaya Uesato; Mikito Mori; Isamu Hoshino; Toru Shiratori; Yukimasa Miyazawa; Hisao Ito; Takashi Uno
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

8.  Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response.

Authors:  Francesca Milano; Luigi Mari; Wendy van de Luijtgaarden; Kaushal Parikh; Silvia Calpe; Kausilia K Krishnadath
Journal:  Front Oncol       Date:  2013-05-29       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.